You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Musculoskeletal Syndrome Trial in Minneapolis (CBD-dominant, THC dominant)

Recruiting
  • Musculoskeletal Syndrome
  • Minneapolis, Minnesota
    University of Minnesota
Jun 28, 2023

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Oct 10, 2022

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor Trial in São Paulo (Tamoxifen)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 13, 2023

Breast Cancer Trial in Boston (Acupuncture, Usual Care)

Active, not recruiting
  • Breast Cancer
  • Acupuncture
  • Usual Care
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 21, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Tianjin, China
    Tianjin Cancer Hospital
Mar 28, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Advanced Breast Cancer
    • Prolonged Overnight Fasting
    • +2 more
    • Phoenix, Arizona
    • +2 more
    Nov 8, 2023

    Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

    Not yet recruiting
    • Locoregional Recurrence
    • +2 more
    • (no location specified)
    Jul 18, 2022

    Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

    Recruiting
    • Breast Cancer
    • Saint Louis, Missouri
    • +2 more
    Jan 12, 2023

    Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

    Recruiting
    • Early-stage Breast Cancer
    • +4 more
    • Trastuzumab and nelatinib
    • Trastuzumab and Parstuzumab
    • Guangzhou, China
      Sun Yat-sen University Sun Yat-sen Memorial Hospital
    Mar 12, 2023

    Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)

    Active, not recruiting
    • Breast Cancer
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Dec 13, 2022

    Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

    Recruiting
    • Locally Advanced or Unresectable Metastatic Breast Cancer
    • Stage IV Breast Cancer
    • Sacituzumab Govitecan-hziy
    • +3 more
    • Marietta, Georgia
    • +1 more
    Apr 21, 2023

    Breast Cancer Trial in Boston (Pembrolizumab, Nab-Paclitaxel, Biopsy)

    Active, not recruiting
    • Breast Cancer
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 22, 2022

    Real-World Data on First-line Treatment of Hormone

    Recruiting
    • Breast Cancer
      • Porto Alegre, Rio Grande Do Sul, Brazil
        CPO
      Aug 15, 2022

      Improving Breast Cancer Hormone Receptor Testing in Tanzania

      Not yet recruiting
      • Breast Cancer
      • Focus group
      • Organizational Readiness for Implementing Change
      • New York, New York
        Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      Jun 24, 2022

      Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

      Not yet recruiting
      • Anatomic Stage I Breast Cancer AJCC v8
      • +5 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Jul 14, 2022